(2S)-2-[(2-aminoacetyl)amino]-N-(2-amino-2-oxoethyl)-4-methylpentanamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-[(2-aminoacetyl)amino]-N-(2-amino-2-oxoethyl)-4-methylpentanamide
• 化学式: C₁₀H₂₀N₄O₃
• 分子量: 244.29
• InChiKey: CXQVELBOUGTEIA-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  127
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-[(3S,6S,9S,12S)-3-(2-amino-2-oxoethyl)-9-butan-2-yl-20-(hydrazinecarbonyl)-12-[(4-hydroxyphenyl)methyl]-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentazacycloicos-6-yl]propanamide 、 (2S)-2-[(2-aminoacetyl)amino]-N-(2-amino-2-oxoethyl)-4-methylpentanamide 生成 N(1)Tyr-xiIle-Gln-Asn-DL-Asu(1)-Gly-Leu-Gly-NH2
  参考文献：
  名称：

  SAKAKIVARA, TOSIXIRA

  摘要：

  DOI：

文献信息

• Molecules that block viral infectivity and methods of use thereof
  申请人：Goobar-Larsson Laura

  公开号：US20070037249A1

  公开（公告）日：2007-02-15

  Embodiments relate to the discovery that certain tripeptide amides and glycine amide can be used to inhibit viral infection, including human immunodeficiency virus (HIV) infection. More specifically, medicaments comprising said tripeptide amides and/or glycine amide and methods of using said compounds for the prevention and treatment of viral infection, such as HIV infection, are provided.
• US7012129B2
  申请人：——

  公开号：US7012129B2

  公开（公告）日：2006-03-14
• [EN] PEPTIDES AS OXYTOCIN AGONISTS<br/>[FR] PEPTIDES EN TANT QU'AGONISTES DE L'OXYTOCINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014095773A1

  公开（公告）日：2014-06-26

  The invention relates to compounds of formula (I) wherein R1 is hydroxy or amino; R2 is sec-butyl or isobutyl; R3 is lower alkyl, lower alkyl substituted by hydroxy, -(CH2)2C(O)-NH2, -(CH2)3-NH2 or -CH2-five membered aromatic heterocyclic group; R4 is hydrogen or lower alkyl; R5 is hydrogen or lower alkyl; or R4 and R5 may form together with the N and C atom to which they are attached a pyrrolidine ring optionally substituted by hydroxy or halogen, a piperidine ring or an azetidine ring; R6 is hydrogen, lower alkyl, lower alkyl substituted by hydroxy, -(CH2)2C(O)OH, -(CH2)2C(O)NH2, benzyl optionally substituted by amino or hydroxy, -CH2-five membered aromatic heterocyclic group, indolyl, -CH2-cycloalkyl, cycloalkyl, -(CH2)2-S- lower alkyl or is -(CH2)1-4-NH2; R6' is hydrogen or lower alkyl; or R6 and R6' are together cycloalkyl; X is -C(O)-CHR-NR'-C(O)-; R/R' are independently from each other hydrogen or lower alkyl; m is 2; O is 0 or 1; or a to pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. It has been found that the present compounds are oxytocin receptor agonists for the treatment of autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawel, drug addiction and for the treatment of Prader-Willi Syndrom.